Yılmaz Songül, Özçakar Z Birsin, Taktak Aysel, Kiremitçi Saba, Ensari Arzu, Dinçaslan Handan, Yalçınkaya Fatoş
Department of Pediatrics, Division of Pediatric Nephrology, Ankara University School of Medicine, Ankara, Turkey.
Çocuk Sağlığı ve Hastalıkları AD, Çocuk Nefroloji Ünitesi, Ankara Üniversitesi Tıp Fakültesi, Dikimevi, Ankara, Turkey.
Pediatr Nephrol. 2016 Jun;31(6):1029-32. doi: 10.1007/s00467-016-3355-z. Epub 2016 Feb 29.
Targeting the vascular endothelial growth factor (VEGF) signaling pathway has become an important approach to current cancer therapy. Anti-VEGF therapy-related renal adverse effects may present as hypertension, non-nephrotic proteinuria, and rarely as nephrotic syndrome (NS) and acute kidney injury.
CASE-DIAGNOSIS/TREATMENT: In this report, we present a 15-year-old boy who had developed nephrotic syndrome and thrombotic microangiopathy 26 months after administration of anti-VEGF therapy. Treatment was discontinued and nephrotic syndrome remitted spontaneously within 3 months.
Nephrologists should be aware of the side effects of anti-VEGF therapy. Early diagnosis and prompt management with withdrawal of the agents will result in spontaneous remission.
靶向血管内皮生长因子（VEGF）信号通路已成为当前癌症治疗的重要方法。抗VEGF治疗相关的肾脏不良反应可能表现为高血压、非肾病性蛋白尿，很少表现为肾病综合征（NS）和急性肾损伤。
病例诊断/治疗：在本报告中，我们介绍了一名15岁男孩，他在接受抗VEGF治疗26个月后出现了肾病综合征和血栓性微血管病。治疗中断，肾病综合征在3个月内自发缓解。
肾脏科医生应意识到抗VEGF治疗的副作用。早期诊断并及时停药处理将导致自发缓解。
